BROOKS LAB LIMITED
BROOKS · General/Diversified · NSE
₹62
Current Market Price
Fair Value (DCF)
₹71
Discount to FV
+14.4%
Updated just now
YieldIQ Score
57/100
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
58%
ROE
-10.2%
Debt/Equity
0.08
WACC
11.1%
Market Cap
₹183.19 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
-6.9%
Return on capital employed
EV / EBITDA
22.1×
Enterprise multiple
Debt / EBITDA
1.1×
Leverage vs earnings
Interest Coverage
-10.5×
EBIT covers interest
Current Ratio
1.48×
Short-term liquidity
Asset Turnover
0.72×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹62.19
Bear case
Discount -35.9%
Base case
Discount +12.6%
Bull case
Discount +33.9%
Ratio Trends
BROOKS · last 8 annual periods
ROE
-10.2%
ROCE
-6.9%
Operating Margin
—
Debt / Equity
0.08×
PE
—
EV / EBITDA
—
Historical Financials
BROOKS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹77.2 Cr | ₹90.1 Cr | ₹62.5 Cr | ₹79.0 Cr | ₹82.2 Cr | +1.6% |
| EBITDA | — | ₹-13.7 Cr | ₹-29.4 Cr | ₹-17.1 Cr | ₹-7.3 Cr | — |
| EBIT | ₹-5.9 Cr | ₹-20.8 Cr | ₹-33.6 Cr | ₹2.4 Cr | — | — |
| PAT | ₹-19.4 Cr | ₹-19.3 Cr | ₹-20.9 Cr | ₹-19.6 Cr | ₹-10.0 Cr | — |
| EPS (diluted) | ₹6.31 | ₹-7.82 | ₹-12.57 | ₹-7.67 | — | — |
| CFO | ₹4.5 Cr | ₹-37.4 Cr | ₹-14.5 Cr | ₹-9.8 Cr | ₹2.5 Cr | -13.3% |
| CapEx | — | ₹-23.2 Cr | ₹-0.5 Cr | ₹-0.4 Cr | ₹-0.9 Cr | — |
| FCF | — | ₹-60.7 Cr | ₹-15.0 Cr | ₹-10.2 Cr | ₹1.6 Cr | — |
| Total Assets | — | ₹196 Cr | ₹110 Cr | ₹90.4 Cr | ₹124 Cr | -10.9% |
| Total Debt | — | ₹25.3 Cr | ₹6.5 Cr | ₹5.6 Cr | ₹7.6 Cr | -26.0% |
| Shareholders' Equity | — | ₹87.5 Cr | ₹74.0 Cr | ₹65.6 Cr | ₹98.1 Cr | +2.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BROOKS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
NATCAPSUQ NATCAPSUQ | — | — | Pending | 0.3% | — |
AAREYDRUGS AAREYDRUGS | — | — | Pending | 2.9% | — |
NECLIFE NECLIFE | — | — | Pending | -11.9% | — |
ALPA ALPA | — | — | Pending | 11.4% | — |
BALPHARMA BALPHARMA | — | — | Pending | 9.3% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BROOKS in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. BROOKS LAB LIMITED (BROOKS.NS) trades at 62.19 vs a model fair value of 71.16, a gap of 14.4%. Piotroski F-score: 6/9. Moat label: Modera...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BROOKS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BROOKS →
Compare
Head-to-head with peers
Compare BROOKS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BROOKSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.